Development of neuromodulating AAV-KCC2 gene therapy to treat paralysis, spasticity and neuropathic pain after spinal cord injury
Ended Project Grant Awarded Last action
- Award ID
- R43NS124434
- Recipient
-
Axonis Therapeutics, Inc. UEI LR1MVZHCSJ95
- Awarding agency
-
National Institute of Neurological Disorders and Stroke
National Institutes of Health, Department of Health and Human Services
- Obligated
- $464,919
Award facts
- Assistance listing
- 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders
- Completion date
- Originally
- Place of performance
- Massachusetts, USA
Award details come from USAspending.gov.
Description
- Abstract
- There are no approved therapies for spinal cord injury. There are about 300,000 people living with chronic spinal cord injury in US. For the vast majority of them, the injury left them incapable of walking or, if they have suffered a cervical SCI, entirely dependent upon others for assistance in all of their activities of daily living from feeding to personal care. We are developing a neuromodulating gene therapy for treating both acute and chronic SCI patients that will be delivered as a single injection to spinal cord. Neuromodulation after injury has the potential to restore functional recovery, as shown by a number of different investigators. After SCI there is an electrochemical imbalance that prevents motor neurons from eliciting normal muscle actions that are critical for movement of arms and legs. This imbalance is partly caused by a decrease in the chloride transporter called KCC2. IT has been shown that by restoring normal levels of this transporter in spared spinal cord neurons, paralyzed mice regain walking ability. Furthermore, enhancement of KCC2 reduces pain and spasticity in rodent models. This grant application aims to examine a new therapy that has the potency and properties to be translated towards human clinical studies, by testing them in preclinical models.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$206,417 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $335,668 | |
| Original award | $335,668 |
Quick answers
Who received award R43NS124434?
R43NS124434 was awarded to Axonis Therapeutics, Inc. by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on September 24, 2022.
How much is award R43NS124434 worth?
$464,919 has been obligated on R43NS124434.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award